相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Challenges and Opportunities from Basic Cancer Biology for Nanomedicine for Targeted Drug Delivery
Xiaodong Xie et al.
CURRENT CANCER DRUG TARGETS (2019)
A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients
Yasuhiro Fujiwara et al.
BRITISH JOURNAL OF CANCER (2019)
Clinical Trials of Thermosensitive Nanomaterials: An Overview
Stefania Nardecchia et al.
NANOMATERIALS (2019)
Transferrin-Conjugated Polymeric Nanoparticle for Receptor-Mediated Delivery of Doxorubicin in Doxorubicin-Resistant Breast Cancer Cells
Zar Chi Soe et al.
PHARMACEUTICS (2019)
Advances in Targeted Therapies for Triple-Negative Breast Cancer
Kelly E. McCann et al.
DRUGS (2019)
Docetaxel-loaded nanostructured lipid carriers functionalized with trastuzumab (Herceptin) for HER2-positive breast cancer cells
Jaleh Varshosaz et al.
JOURNAL OF LIPOSOME RESEARCH (2018)
Characteristics, Properties and Analytical Methods of Paclitaxel: A Review
Renata Carolina Alves et al.
CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY (2018)
Stimuli-responsive polymeric micelles for drug delivery and cancer therapy
Qing Zhou et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
Current development in the formulations of non-injection administration of paclitaxel
Xiyou Du et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2018)
Ursolic acid a promising candidate in the therapeutics of breast cancer: Current status and future implications
Javed Iqbal et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Liposomal cisplatin response prediction in heavily pretreated breast cancer patients: A multigene biomarker in a prospective phase 2 study.
Erik Hugger Jakobsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study
Minjun Dong et al.
ONCOTARGETS AND THERAPY (2018)
Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization
K. Laxmi Swetha et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2018)
PEGylated Poly(alpha-lipoic acid) Loaded with Doxorubicin as a pH and Reduction Dual Responsive Nanomedicine for Breast Cancer Therapy
Huailin Yang et al.
BIOMACROMOLECULES (2018)
Epirubicin-loaded polymeric micelles effectively treat axillary lymph nodes metastasis of breast cancer through selective accumulation and pH-triggered drug release
Tsukasa Chida et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Role of Endothelium in Doxorubicin-Induced Cardiomyopathy
Albert Z. Luu et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2018)
Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
Alina Uifalean et al.
PHARMACEUTICS (2018)
Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience
Patricia Martin-Romano et al.
BREAST JOURNAL (2018)
Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy
Josimar O. Eloy et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2017)
Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer
Xiaoqiu Wu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Targeted multidrug delivery system to overcome chemoresistance in breast cancer
Yuan Tang et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2017)
Targeted co-delivery of polypyrrole and rapamycin by trastuzumab-conjugated liposomes for combined chemo-photothermal therapy
Hanh Thuy Nguyen et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2017)
Paclitaxel: What has been done and the challenges remain ahead
Ezequiel Bernabeu et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2017)
Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations
Ruijuan Luo et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2017)
Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation
Mona Alibolandi et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Targeted cancer therapy through antibody fragments-decorated nanomedicines
Abbas Alibakhshi et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Nanocarriers in cancer clinical practice: a pharmacokinetic issue
Luciana Giodini et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2017)
Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials
Yun Liu et al.
ONCOTARGET (2017)
An Open-Label, Randomized, Parallel, Phase Ill Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer
In Hae Park et al.
CANCER RESEARCH AND TREATMENT (2017)
Liposomal Formulations in Clinical Use: An Updated Review
Upendra Bulbake et al.
PHARMACEUTICS (2017)
Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes
Mari C. Asensio-Lopez et al.
PLOS ONE (2017)
Folic acid and trastuzumab conjugated redox responsive random multiblock copolymeric nanocarriers for breast cancer therapy: In-vitro and in-vivo studies
Arun Kumar et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2017)
New Advances in Nanotechnology-Based Diagnosis and Therapeutics for Breast Cancer: An Assessment of Active-Targeting Inorganic Nanoplatforms
Priscila Falagan-Lotsch et al.
BIOCONJUGATE CHEMISTRY (2017)
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
Andrea Rocca et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
John M. Lambert et al.
ADVANCES IN THERAPY (2017)
Clinical Practice Guidelines on the Evidence-Based Use of Integrative Therapies During and After Breast Cancer Treatment
Heather Greenlee et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Herceptin-conjugated temperature-sensitive immunoliposomes encapsulating gemcitabine for breast cancer
Dae Hwan Shin et al.
ARCHIVES OF PHARMACAL RESEARCH (2016)
A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle
Howard A. Burris et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
Elizabeth Pham et al.
CANCER RESEARCH (2016)
New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy
Alberto A. Gabizon et al.
DRUG RESISTANCE UPDATES (2016)
Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells
Kongtong Yu et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors
Hirofumi Mukai et al.
INVESTIGATIONAL NEW DRUGS (2016)
Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer
Michail Ignatiadis et al.
PLOS ONE (2016)
Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity
Hiroshi Maeda
ADVANCED DRUG DELIVERY REVIEWS (2015)
Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes
Esther Tahover et al.
ANTI-CANCER DRUGS (2015)
Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study
Miguel J. Gil-Gil et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
Ken-ichi Fujita et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Anti-tumor activity of paclitaxel through dual-targeting lipoprotein-mimicking nanocarrier
Conghui Chen et al.
JOURNAL OF DRUG TARGETING (2015)
Thermosensitive Liposome Formulated Indocyanine Green for Near-Infrared Triggered Photodynamic Therapy: In Vivo Evaluation for Triple-Negative Breast Cancer
Colby S. Shemesh et al.
PHARMACEUTICAL RESEARCH (2015)
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)
A. Awada et al.
ANNALS OF ONCOLOGY (2014)
Pegylated liposomal doxorubicin in the management of ovarian cancer A systematic review and metaanalysis of randomized trials
Nicoletta Staropoli et al.
CANCER BIOLOGY & THERAPY (2014)
Treatment innovations for metastatic breast cancer: Nanopartiele albumin-bound (NAB) technology targeted to tumors
Ana Lluch et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target
Jianguo Feng et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Phase I/II clinical study on safety and antivascular effects of paclitaxel encapsulated in cationic liposomes for targeted therapy in advanced head and neck cancer
Sebastian Strieth et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2014)
Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy: A multicenter phase III study
V. Lorusso et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
A Phase II Trial of Neoadjuvant Chemotherapy with Genexol® (Paclitaxel) and Epirubicin for Locally Advanced Breast Cancer
Jinsun Lee et al.
JOURNAL OF BREAST CANCER (2014)
Preparation, Characterization, and Pharmacodynamics of Thermosensitive Liposomes Containing Docetaxel
Hui Zhang et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
What nanomedicine in the clinic right now really forms nanoparticles?
Sonke Svenson
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY (2014)
Paclitaxel Formulations: Challenges and Novel Delivery Options
Chetan Nehate et al.
CURRENT DRUG DELIVERY (2014)
Standardized radiofrequency ablation (sRFA) ≥ 45 minutes (m) plus lyso-thermosensitive liposomal doxornbicin (LTLD) for solitary hepatocellular carcinoma (HCC) lesions 3-7 cm: A retrospective analysis of phase III HEAT study.
Riccardo Lencioni et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India
A. A. Ranade et al.
ANNALS OF ONCOLOGY (2013)
A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies
John F. Deeken et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, NanoxelTM
Alka Madaan et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2013)
Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) Formulation and Paclitaxel in Polyethoxylated Castor Oil: A Randomized, Two-Period Crossover Study in Patients With Advanced Cancer
Marije Slingerland et al.
CLINICAL THERAPEUTICS (2013)
Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts
Liang Ye et al.
FOOD AND CHEMICAL TOXICOLOGY (2013)
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies
Glen J. Weiss et al.
INVESTIGATIONAL NEW DRUGS (2013)
Hypersensitivity reaction studies of a polyethoxylated castor oil-free, liposome-based alternative paclitaxel formulation
Hongbo Wang et al.
MOLECULAR MEDICINE REPORTS (2013)
Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial
D. Rayson et al.
ANNALS OF ONCOLOGY (2012)
Nanomedicine
Frank Caruso et al.
CHEMICAL SOCIETY REVIEWS (2012)
Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer
Ken Kato et al.
INVESTIGATIONAL NEW DRUGS (2012)
Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study
Christoph Mamot et al.
LANCET ONCOLOGY (2012)
Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention
Janos Szebeni et al.
ADVANCED DRUG DELIVERY REVIEWS (2011)
Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I-II)
M. S. Rosati et al.
ANNALS OF ONCOLOGY (2011)
Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer
Silvia Dellapasqua et al.
BREAST (2011)
Myotax: A phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines
E. Curtit et al.
EUROPEAN JOURNAL OF CANCER (2011)
A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer
D. Amadori et al.
EUROPEAN JOURNAL OF CANCER (2011)
Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity
Jerzy Gubernator
EXPERT OPINION ON DRUG DELIVERY (2011)
Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer
Ronnie T. P. Poon et al.
FUTURE ONCOLOGY (2011)
Adverse drug reaction profile of nanoparticle versus conventional formulation of paclitaxel: An observational study
Ballari Brahmachari et al.
INDIAN JOURNAL OF PHARMACOLOGY (2011)
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer
M. Venturini et al.
BREAST (2010)
Phase II Trial of Combination of Pegylated Liposomal Doxorubicin, Cisplatin, and Infusional 5-Fluorouracil (CCF) Plus Trastuzumab as Preoperative Treatment for Locally Advanced and Inflammatory Breast Cancer
Rosalba Torrisi et al.
CLINICAL BREAST CANCER (2010)
Influence of Polyethyleneglycol Modification on Phagocytic Uptake of Polymeric Nanoparticles Mediated by Immunoglobulin G and Complement Activation
Anshu Yang et al.
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY (2010)
Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release
Chris Oerlemans et al.
PHARMACEUTICAL RESEARCH (2010)
Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics
Danbo Yang et al.
Cancers (2010)
A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors
Qian Zhang et al.
BIOMEDICINE & PHARMACOTHERAPY (2009)
Preclinical Results of Camptothecin-Polymer Conjugate (IT-101) in Multiple Human Lymphoma Xenograft Models
Tontanai Numbenjapon et al.
CLINICAL CANCER RESEARCH (2009)
Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer
David Rossi et al.
ANTI-CANCER DRUGS (2008)
Nine months to progression using fourth-line liposomally encapsulated paclitaxel against hepatocellular carcinoma
Maximilian Christopeit et al.
CHEMOTHERAPY (2008)
Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel
Gerald J. Fetterly et al.
CLINICAL CANCER RESEARCH (2008)
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
Keun Seok Lee et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells
Tao Yang et al.
PHARMACEUTICAL RESEARCH (2007)
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer
Marshall R. Posner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation
T. Hamaguchi et al.
BRITISH JOURNAL OF CANCER (2007)
Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer
Vernon Harvey et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel
N Desai et al.
CLINICAL CANCER RESEARCH (2006)
Camptothecin: current perspectives
CJ Thomas et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2004)
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation
H Gelderblom et al.
EUROPEAN JOURNAL OF CANCER (2001)
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer
G Batist et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
